Activation of the mitogen-activated protein kinase (MAPK) cascade is a well documented mechanism for the G-protein-coupled receptors. Here, we have analysed the requirements for ERKs and p38 MAPK activation by thrombin in Jurkat T cells. We show that thrombinmediated ERKs activation requires both PTK and PKC activities, whereas p38 MAPK activation is dependent only on PTKs. Thrombin-induced ERK and p38 MAPK activation was more pronounced in p56Lck de®cient cells indicating that this PTK exerts a negative control on MAPK activity. Accordingly, overexpression of p50 Csk a kinase that inactivates p56Lck induced constitutive activation of ERKs. Requirement for a Src kinase was evidenced by expression of a constitutively active form of p59Fyn in Jurkat cells. Besides its eect on tyrosine phosphorylation events, thrombin also triggered a rapid and robust redistribution of PKCe and d from the cytosol to the membrane. Expression of constitutively active and dominant negative PKCe demonstrates the pivotal role of this PKC isoform in ERKs activation by thrombin. These data are consistent with a model where thrombin induces ERK activation via both PKC-dependent and independent pathways, whereas p38 MAPK activation requires only PTKs. The PKC-independent pathway requires Src kinases other than p56Lck more likely p59Fyn, while the PKC-dependent mechanism depends on PKCe Oncogene (2001) 20, 1964 ± 1972. 
Introduction
The thrombin receptor is a member of the seven transmembrane domain receptor family that can transduce mitogenic stimulation by coupling to heterotrimeric G proteins Gi and Gq, leading to inhibition of adenylate cyclase and activation of phospholipase C respectively (Vu et al., 1991) . Receptor activation occurs through proteolysis by thrombin at a speci®c site in the N-terminal portion of the receptor unmasking a sequence that functions as a ligand for the receptor. The thrombin receptor is ubiquitously expressed but its role is particularly well documented in platelets in which receptor activation results in aggregation and granule secretion (Dery et al., 1998) . In T lymphocyte, we and others have previously shown that thrombin and its agonist peptide triggered an increase in intracellular Ca 2+ , tyrosine phosphorylation of several cellular proteins and activation of the three MAPK pathways (ERKs, JNK and P38 MAPK) (Maulon et al., 1998; Mari et al., 1994; Joyce et al., 1997) .
The ERK cascade plays a critical role in the regulation of cell proliferation as well as in the control of cell dierentiation, whereas JNK/P38 MAPK are activated following cellular stresses such as osmotic shock, UV irradiation or stimulation by in¯ammatory cytokines such as IL1 and TNFa. The pathways involved in the activation of these MAPK cascades have been well established for ERK1/2 but are not fully understood for JNK/P38 MAPK. ERK1/2 are activated by phosphorylation of both threonine and tyrosine residues catalysed by MAPK kinases, namely MEK1 and MEK2 (Anderson et al., 1990) . MEKs are in turn regulated by serine phosphorylation by several MAPK kinase kinases (MKKKs), including Raf-1. The regulation of Raf-1 is particularly complex. This kinase is controlled by both phosphorylation and relocalization to the plasma membrane (Morrison et al., 1993; Stokoe et al., 1994) , a mechanism involving the small G protein GTP-Ras. Upstream elements of the cascade are not well characterized. ERK pathway triggered by GPCRs was shown to be sensitive to genestein (Sadoshima and Izumo, 1996; Wan et al., 1996; Conway et al., 1999) , suggesting the involvement of tyrosine kinases. More precisely, several recent studies have implicated Src kinases in GPCR-mediated activation of the ERK1/2 pathway. Thus, Src kinases are likely to be the link between receptor stimulation and activation of the Ras/MAPK cascade. Among the mechanisms reported, there is evidence of both PKCdependent and independent pathways. Concerning PKC-dependent mechanisms, it is well established that phorbol esters lead to a rapid and massive activation of ERK1/2 in most cell types (Rossomando et al., 1989) . While both conventional PKCs (cPKCs) like a, b1, b2 and g, and novel PKCs (nPKCs) such as d, e, y and Z are activated by PMA, only cPKCs are Ca 2+ dependent. Atypical PKCs (aPKCs) such as z and i/l are neither activated by Ca 2+ nor phorbol esters, although they can bind DAG. The existence of a family of PKC isotypes suggests that individual PKCs may exert speci®c roles in signal transduction. In vitro, PKCa and PKCe have been shown to activate Raf-1 (Cai et al., 1997) and to regulate transcription factors including AP-1 and NF-kB (Genot et al., 1995) . Implication of PKCl and PKCz in the regulation of the MAPK pathway has also been reported (Bjorkoy et al., 1997; Diaz et al., 1994) . More recent studies have also evidenced PKCy as a regulator of JNK activation in response to T cell receptor stimulation (Werlen et al., 1998; Ghaari et al., 1999) . However, at present less is known about the role of speci®c PKC isoforms in the regulation of P38 MAPK activation. P38 MAPK activation is regulated by phosphorylation on both threonine and tyrosine residues by either MKK3 or MKK6, themselves activated by dierent MKKKs such as Ask1 or PAK (Wang et al., 1998) .
In the present study, we sought to determine the mechanisms by which thrombin activates the ERK1/2 and p38 MAPK cascades with particular relevance to speci®c tyrosine kinase and PKC isoform dependence. Our data indicate that PKC and Src tyrosine kinases represent two independent pathways both involved in thrombin-mediated ERK activation whereas P38 MAPK activation requires only tyrosine kinases. Moreover, using speci®c inhibitors, we show that nPKCs are involved in the activation of the Raf/ MEK/ERK pathway. Finally, dominant-negative and constitutively active p59Fyn and PKC mutants allowed us to evidence the crucial role of p59Fyn and PKCe in thrombin-mediated ERK1/2 activation in T lymphocytes.
Results

Thrombin-mediated activation of ERK and P38 MAPK in T cells requires tyrosine kinase activities
In a previous report, we have established that thrombin induces the phosphorylation of several proteins on tyrosine residues and noticeably leads to activation of the three MAPK pathways in T lymphocytes (Maulon et al., 1998) . To better assess the requirement of protein tyrosine kinases (PTK) in thrombin-induced P42/44 and P38 MAPK activation, we utilized selective pharmacological inhibitors. Thrombin-mediated ERK1/2 activation was observed in both JE6.1 and JCaM1 cells (Figure 1a , compare lanes 1 and 2, 7 and 8) indicating that ERK1/2 can be activated even in the absence of p56LcK. Interestingly, ERK1/2 activation was even more pronounced in JCaM1 cells compared to JE6.1 in agreement with our previous observation that p56lck exerts a negative control on thrombin responses in T cells (Maulon et al., 1998) . When both cell types were pretreated with herbimycin A, a PTK inhibitor, thrombin induced-MAPK activation was potently inhibited at 5 mM (Figure 1a , lanes 6 and 12). We also checked that the highest dose in this experiment was not toxic for T lymphocytes (data not shown). Herbimycin A was also found to inhibit thrombin-induced p38 MAPK activation (Figure 1b , lane 6). Taken together, these data indicate that Figure 1 Eect of the tyrosine kinase inhibitor Herbimycine on thrombin-induced MAPK activation. JE6.1 or JCaM1 cells were pretreated overnight with the indicated dose of herbimycine A and then stimulated with thrombin (5 U/ml) for 1 min. MAPK activity was assessed using phosphospeci®c antibodies as described previously. Equal amounts of MAPK were detected in each condition (not shown). A representative experiment is shown thrombin-mediated p42/44 and p38 MAPK activation in Jurkat T cells requires PTKs dierent from p56lck.
To determine whether Src family kinases were involved in thrombin-induced p42/44 and P38 MAPK activation we ®rst examined the eect of the speci®c Src kinase inhibitor PP2. Interestingly, PP2 alone was found to induce ERK1/2 phosphorylation in JE6.1 but not JCaM1 cells, an observation in agreement with the negative eect of p56Lck on thrombin responses in T lymphocytes (Figure 2a, lanes 4 and 10) . In both cell type, the thrombin-induced ERK1/2 phosphorylation was inhibited by PP2 as was anti-CD3-mediated ERK1/2 phosphorylation ( Figure 3a , lanes 5, 6, 11 and 12), indicating that a member of the Src family kinase dierent from p56lck was involved in thrombininduced ERK1/2 activation in Jurkat T cells. P38 MAPK phosphorylation was followed in JCaM1 (Figure 2b ). Thrombin-induced p38 MAPK kinase phosphorylation (lane 2) was abolished by PP2 ( Figure  2b , lane 5). This observation is also in favour of the requirement of a Src kinase dierent from p56lck in p38 MAPK activation by thrombin.
P59Fyn mediated ERK1/2 activation
To assess the requirement of Src kinases on thrombinmediated ERK1/2 activation, we transiently transfected wild type and constitutively active p59Fyn (Y531F) in J6E.1 cells. p59Fyn expression was followed by Western blotting with a speci®c anti-p59Fyn antibody. p59Fyn expression was slightly but signi®cantly increased in cells transfected with either wild type or Y531F-Fyn (Figure 3b ). In mock-transfected cells and Fyn wild type transfected cells, thrombin increased ERK1/2 phosphorylation threefold above basal ( Figure  3a) . Interestingly, expression of a constitutively activated Fyn (Y531F-Fyn) in JE6.1 cells was accompanied by a six-and ninefold increase in p42/44MAPK phosphorylation in untreated and thrombin-stimulated cells respectively (Figure 3a ).
Csk is involved in thrombin-induced ERK1/2 activation
The requirement for a Src kinase in thrombin-induced p42/44 MAPK activation was further studied by using transiently transfected p50Csk-HA Jurkat cells. Csk is a cytoplasmic PTK that phosphorylates and inactivates Src family kinases (Nada et al., 1993) . We checked that overexpression of p50 Csk-HA could be detected by Western blotting with anti-HA antibodies in pEF-Csk-HA, but not in pEF-HA transfected cells (Figure 4a) . Surprisingly, we established that overexpression of p50Csk leads to basal activation of ERK1/2 in Jurkat T cells, an eect that was not further increased by thrombin treatment (Figure 4c ). Finally, in an in vitro kinase assay we observed that thrombin did not signi®cantly stimulate p50Csk activity. This observation indicates that p50Csk could exert a positive role in ERK1/2 activation likely by phosphorylating and inactivating p56lck (Figure 4b ).
Thrombin-mediated ERK1/2 but not p38 MAPK activation is dependent on PKC
Phorbol ester treatment of Jurkat cells leads to ERK1/ 2 phosphorylation and activation ( Figure 5a ). In JCaM1 cells the extent of phosphorylation was found to be similar to that observed in the presence of Figure 2 Eect on PP2 on thrombin-induced MAPK activation. Cells were pretreated with 25 mM of PP2 for 30 min and then stimulated with either 5 mg/ml of anti-CD3 for 2 min or 5 U/ml of thrombin for 1 min. MAPK activity was detected with phosphospeci®c antibodies. Equal amounts of MAPK were detected in each condition (not shown). Results shown are representative of three dierent experiments thrombin. Thus, it was of interest to investigate the role of PKCs in thrombin-induced ERK1/2 activation. In this aim, we ®rst used GF 109203X an inhibitor of both classical and new isoforms of PKCs. As illustrated in Figure 5a , pretreatment of both JE6.1 and JCaM1 cells with 2 mM of GF109203X abolished ERK1/2 activation in response to a maximally eective concentration of PMA (10 ng/ml). Thrombin-induced ERK1/2 activation was partially inhibited in JE6.1 cells whereas the eect of thrombin was abolished in JCaM1 cells ( Figure 5a ). As GF109203X inhibits both classical and novel PKCs, we sought to determine precisely which PKC isoforms were involved in thrombin-induced ERK1/2 activation. Thus, we took advantage on the property of GoÈ 6976 to block only cPKCs. Thrombin-induced ERK1/2 was unaected in JE6.1 and JCaM1 cells pretreated with GoÈ 6976 up to 2 mM (Figure 5b ), suggesting that thrombin-induced ERK1/2 phosphorylation and activation is independent on cPKCs in Jurkat cells. Finally, thrombin-mediated activation of p38 MAPK was increased by GF109203X and by GoÈ 6976, suggesting that thrombin-mediated p38MAPK phosphorylation and activation is repressed by both c and nPKCs (Figure 5c ). Finally, the eect of PMA on p38 MAPK activation was potently inhibited by GF 109203X but not by GoÈ 6976 (Figure 5c ).
PKC e and d are the main PKC isotypes activated by thrombin in Jurkat T cells
At least 10 PKC isoforms are present in Jurkat cells, some of which may play speci®c roles in signal transduction a, b1, e, d, y, Z and z (Mari et al., 1997) . As thrombin-mediated ERK1/2 is likely to be dependent on nPKCs, we assessed the expression of e, d and y PKCs by Western blotting using anti-speci®c isoform antibodies. Activation of PKCs required their relocalization from the cytoplasm to the membrane fraction. Thus, we followed the relocalization of e, d and y PKCs upon thrombin treatment of both JE6.1 and JCaM1 cells (Figure 6 ). In unstimulated T lymphocytes we failed to detect any membrane associated PKCe whereas small amounts of PKCd and PKCy were already present in the microsomal fraction of unstimulated Jurkat T cells ( Figure 6 , lanes 1 and 6). PKCy was moderately redistributed in the particulate fraction following thrombin treatment in both cell lines, compared to PMA treated cells used as a positive control of translocation (lanes 2 ± 4 and 5, lane 7 ± 9 and 10). Interestingly, thrombin was found to induce a rapid and robust redistribution of PKCe and d (i.e. nearly identical to that observed in the presence of PMA) into the membrane fraction of both JE6.1 and JCaM1 cells indicating that PKCe and d could PKCe is required for thrombin-induced ERK1/2 activation A mutant isoform of PKCe in which an alanine has been replaced by a glutamate within the pseudosubstrate domain (PKCe A159E) that introduces a negative charge mimicking the presence of phosphate residue is constitutively activated. By contrast, replacement of a lysine at the ATP binding site by an arginine (PKCe K436R) generates a kinase-defective PKCe. When overexpressed in recipient cells this mutant competes with the endogenous wild type enzyme and acts as a selective dominant negative inhibitor (Ghaari et al., 1999) . The expression of the PKC mutants in transiently transfected JE6.1 cells was analysed by immunoblotting with isoenzyme-speci®c antibodies (Figure 7a ). Transfection by vectors encoding mutants of PKCe led to an overexpression of isoform e. As depicted in Figure 7b , overexpression of a catalytically active PKCe isoforms resulted in basal activation (i.e: in the absence of thrombin) of ERK1/2 (compare lanes 1 and 3). While demonstrating a role for PKCe in ERK1/2 activation these data are however not sucient to conclude that this speci®c isoform is implicated in thrombin-induced p42/44MAPK activation in T lymphocytes. To better de®ne the speci®c isoforms of PKC required for thrombin-mediated ERK1/2 activation, we transfected a dominant negative mutant of PKCe into JE6.1 cells. Overexpression of a dominant negative mutant of PKCe drastically inhibited thrombin eect on ERK1/2 activation. All together these results strongly support a role for PKCe in thrombin-induced ERK1/2 activation in T lymphocytes. Finally, overexpression of DN-PKCy and d did not inhibit thrombin-induced ERK1/2 activation in Jurkat cells (not shown).
Discussion
Although little is known about the molecular basis of thrombin action in T lymphocytes, we and others have Figure 5 Eect of the PKC inhibitors GF109203X and GoÈ 6976 on thrombin-induced MAPK activation. JCaM and JE6.1 cells were preincubated for 30 min at 378C in either the absence or the presence of 2 mM GF109203X (a,c), or with increasing doses of GoÈ 6976 (b). Cells were then stimulated with PMA (10 ng/ml) or thrombin (5 U/ml) for 1 min. ERK1/2 (a,b) and p38 MAPK (c) activities were assessed with phosphospeci®c antibodies. Equal amounts of MAPK were detected in each condition (not shown). Data are representative of at least three dierent experiments previously characterized a cross-talk between signaling components of the T cell receptor and that of the thrombin activation pathway in Jurkat T cells (Maulon et al., 1998; Joyce et al., 1997) . Noticeably, we brought evidence that the tyrosine kinase p56lck exerted a negative eect on both ERK1/2 and p38 MAPK activation (Maulon et al., 1998) . In the present study, we examined in detail the requirements for activation of the ERK1/2 and p38 MAPK pathways upon thrombin stimulation of T lymphocytes, focusing our attention on both Src kinases and speci®c isoforms of PKCs. We show that thrombin may activate ERK1/2 through two distinct mechanisms, one PKC-independent and the second dependent on both PKC and the Raf/MAPK pathway. By contrast, thrombin-induced p38 MAPK activation appears independent on PKCs but requires activation of PTKs.
The mechanisms by which non-receptor and receptor-tyrosine kinases can regulate cell growth and dierentiation has been extensively studied (Burgering and Bos, 1995) . The prototype and the best characterized tyrosine kinase receptor is certainly EGFR (Marshall, 1995) . EGF binding to its receptor results in receptor dimerization and autophosphorylation. The tyrosine phosphorylated residues in the cytoplasmic domain of the EGFR can serve as anchors for the SH2 domains of adaptor proteins such as Shc, which in turn can recruit the Grb2-Sos complex resulting in activation of the Ras/Raf/MAPK pathway (Buday and Downward, 1993; Medema et al., 1993) . The mechanisms by which serpentine receptors activate the MAPK pathway is more complex since a peculiar GPCR can perfectly be coupled to several dierent G proteins. It is now well established that many GPCRs regulate MAPK cascades, leading to activation of ERKs, JNK and p38 MAPK, which function as transcriptional regulators (Gutkind, 1998) . Translocation of PKC isozymes in thrombin-stimulated Jurkat cells. Proteins contained in particulate fractions (P100) prepared from Jurkat cells treated with 5 U/ml thrombin for the indicated time or 10 ng/ml PMA for 5 min were loaded on 10% SDS ± PAGE and transferred to immobilon membranes for Western blotting with PKC-isoform-speci®c antibodies. Blots were further incubated with horseradish peroxydase-conjugated secondary antibody and immunoreactivity was detected by enhanced chemoluminescence In the present study, thrombin-induced ERK1/2 and p38 MAPK activation were both found to be sensitive to tyrosine kinase inhibition. Members of the Src nonreceptor tyrosine kinase family are sought to play an important role in thrombin-mediated ERK1/2 activation in human platelets and ®broblasts (Satoh et al., 1996; Chen et al., 1994) . To investigate the role of the Src kinases in ERK1/2 and p38 MAPK activation by thrombin we looked for the eect of the Src kinase inhibitor PP2 on parental and Lck de®cient Jurkat cells (Hanke et al., 1996) . We found that thrombininduced activation of both MAPK pathways was potently inhibited by PP2, indicating that Src kinase are required for thrombin-induced Erk1/2 and p38MAPK activation. The Src kinases involved in thrombin-induced MAPK activation in T cells have not as yet been identi®ed. Our results clearly demonstrate that p56lck is not required for ERK1/2 and p38 MAPK activation, since these two pathways can be activated in JCaM1 cells which are totally defective for p56Lck expression. Paradoxically, ERK1/ 2 activation was even more pronounced in the absence of p56Lck. At ®rst glance, owing to the inhibitory eect of p56lck on Erk1/2 phosphorylation, it seems surprising that no basal ERK1/2 phosphorylation can be observed in JCaM-1 cells which are de®cient for Lck. However, other signalling molecules such as CD45, Csk and other Src kinases could also aect the level of phosphorylation of ERK1/2. Noticeably, other tyrosine kinases such as p59Fyn could perfectly be responsible for ERK1/2 and p38 MAPK activation by thrombin in Jurkat T cells (Branch and Mills, 1995) . Moreover, the eect of PP2 on JE6.1 and JCaM1 cells is in good agreement with a global inhibitory role of Lck and a stimulatory function of Fyn on ERK1/2 phosphorylation, respectively. The amount of Lck in JE6.1 cells is at least 10 times higher than that of Fyn (not shown). Thus, one can assume that PP2 eect in JE6.1 cells essentially re¯ects the action of the inhibitor on Lck that would lead to the removal of the Lck inhibitory signal and thus to an increase of ERK1/2 phosphorylation. Conversely, the eect of PP2 on JCaM1 cells re¯ects mainly the inhibition of Fyn that would be compatible with the lack of ERK1/2 phosphorylation observed. In the same line, we also show that overexpression of either p50Csk which is a negative regulator of Src kinases or constitutively active Y531F Fyn in Jurkat cells both eciently activates ERK1/2 in either the absence or the presence of thrombin. In our experiments, despite a complete inhibition of tyrosine kinase activities, we still observed a signi®cant residual thrombin-induced ERK1/2 activation in Jurkat T cells, more particularly in JCaM1 cells. This suggests that thrombin used at least an alternative pathway to stimulate ERK. Evidence that this additional signaling mechanism is transmitted by PKC comes from the observation that Jurkat cells treated with the PKC inhibitor GF 109203X that acts on both c and n-PKCs, exhibited a profound inhibition of ERK1/2 activation. Conversely, we observed that GoÈ 6976 that only targets cPKCs was totally ineective. These observations suggest a role for novel PKC isoforms in thrombininduced ERK1/2 activation in T lymphocytes. By Western blotting experiments we could also determine that PKC d, y and e rapidly translocated from the cytosol to the membrane fraction following thrombin stimulation. Interestingly, a massive redistribution was clearly observed for the e and d isoforms. It seems unlikely that all three PKC isoforms participate in thrombin-induced ERK1/2 activation. As shown recently, PKCy is more probably linked to the JNK/ SAPK pathways in T lymphocytes (Ghaari et al., 1999) and PKCy redistribution following thrombin stimulation of Jurkat cells is weak (Figure 6 ). To better characterize the nPKC isoforms implicated in thrombin-induced ERK1/2 activation, we transfected constitutively active and dominant negative isoforms of PKCs in Jurkat cells. We showed unambiguously that CA-PKCe and DN-PKCe were capable to signi®cantly activate and inhibit ERK1/2 activation respectively. CA-PKCa and PKCy were also found to induce signi®cant ERK1/2 activation but an implication of these peculiar isoforms appears unlikely since DNPKCa and DN-PKCy failed to interfere with thrombin-induced ERKs activation (data not shown). Finally, we assessed the possible implication of PKCd. Participation of PKCd was conceivable since: (i) expression of PKCd in COS-1 cells caused activation of MEK1 and ERKs (Ueda et al., 1996) ; and (ii) a robust redistribution of PKCd to the membrane is also observed in Jurkat T cells following thrombin stimulation. However, transfection of DN-PKCd in JE6.1 cells did not signi®cantly inhibit thrombin-induced ERK1/2 phosphorylation, strongly suggesting that this isoform is not involved in this process (not shown). Finally, we cannot totally rule out the participation of atypical PKCs in the thrombin eect. In this line, Bjorkoy et al. (1997) have shown that DN-PKCl interfered with the activation of ERK in v-Ras transformed NIH3T3. It has also been demonstrated that a PKC-dependent activation cascade including both PKCe and PKCz is involved in the activation of the c-fos promoter in HRas transformed cells (Kampfer et al., 1998) . Thus, it appears that the mechanisms underlying the eect of speci®c PKC isoforms are complex and may follow a certain hierarchy. Further work will be necessary to determine exactly the nature and the hierarchy of the concerned isoforms. Nevertheless, our data represent a starting point for a better understanding of the thrombin receptor signaling in T cells.
Thrombin-mediated ERK1/2 activation was totally inhibited in the presence of both herbimycin A and GF 103209X, indicating that PKC and PTK-dependent signaling pathways contributed independently to ERK activation. Song et al. (1998) have evidenced a novel regulatory pathway mediated by the interaction of PKCd with Src and Lyn in RBL-2H3 mast cells that results in phosphorylation of the tyrosine kinases on serine residues and leading to an increase in their activities. In the present study we observed a drastic decrease in thrombin-induced tyrosine phosphorylation in cells treated with GF 109203X. This eect can be attributed to a decrease in Src kinase activity. As we observed that PKCe and p59Fyn are involved in thrombin-induced ERK1/2, a possible scenario would be that activation of PKCe increased p59Fyn activity resulting in phosphorylation and activation of ERK1/ 2. This attractive hypothesis is reinforced by the occurrence of a direct interaction of PKCy and p59Fyn that increases p59Fyn activity (Ron et al., 1999) and by the fact that association of PKCd with Src kinases has been already reported in mast cells (Kawakami et al., 1995; Yao et al., 1994) but the functional consequences of such an interaction remained unknown. Nevertheless, this cross-talk between speci®c PKC isoforms and non-receptor tyrosine kinases may represent an important mechanism for the regulation of the activity of both partners.
Finally, the focal adhesion represents an alternative pathway by which GPCRs can regulate ERK activation. According to the cell type, ERK activation can be linked or dissociated from p125 FAK of Pyk2 activation (Dikic et al., 1996; Luttrell et al., 1997) . In haematopoietic cells, calcium-dependent Pyk2 activation results in stimulation of the ERK cascade (Dikic and Schlessinger, 1998) . Moreover bradykinin stimulation of PC12 cells induces Pyk2 activation, Src recruitment, Src-mediated phosphorylation and binding of Grb2. This activation of Pyk2 depends on calcium and PKC. An implication of Pyk2 in thrombin-induced ERK1/2 activation is unlikely since we found that thrombin failed to activate Pyk2 in Jurkat T cells (not shown). Conversely, thrombin stimulation results in a robust tyrosine phosphorylation of p125 FAK but the kinetics of induction of p125FAK and ERK1/2 phosphorylation were not compatible (not shown).
In conclusion, in this study, we have demonstrated that thrombin induces ERK1/2 activation in T lymphocytes through both PKC-dependent and independent pathways, whereas p38 MAPK activation by thrombin is largely independent on PKCs. The PKCindependent pathway of ERK1/2 activation involves Src kinases more likely p59Fyn while the PKCdependent mechanism requires PKCe.
Materials and methods
Reagents and plasmids
Biotin-conjugated (4G10) antibody was purchased from UBI (Upsdate Biotechnology Incorporated), phospho-p38 MAPK (Thr 180, Tyr 182) antibody from Promega, and phospho-ERK1/2 antibody from New England Biolabs. Peroxydaseconjugated secondary antibody was obtained from DAKO. Bovine thrombin (stock solution 1000 U/ml) was purchased from Sigma. Antibodies directed against the dierent isoforms of PKC were obtained from transduction laboratory (Lexington, KY, USA). PKC inhibitors, GFX 109203X and GoÈ 6976 were from Calbiochem (La Jolla, CA, USA). PKCy, PKCe, PKCd and PKCa wild type cDNA were subcloned into pEF-neo. Site directed mutagenesis of PKC cDNA was performed with the transformer system (Clontech, Palo Alto, CA, USA) as previously described (Baier et al., 1996) .
Cell lines and transfection protocol
Jurkat leukaemic cell lines JCaM1 and JE6.1 were kindly provided by Dr Arthur Weiss (University of California, CA, USA) and have been described elsewhere (Maulon et al., 1998; Goldsmith and Weiss, 1987; Weiss and Littman, 1994) . Jurkat cells and Jurkat-Tag stably expressing the SV40 large T antigen, a kind gift of Dr G Crabtree, University of California were maintained in RPMI 1640 medium supplemented with 5% Foetal Calf Serum and antibiotics at 378C. Transient or stable transfection of Jurkat cells were realized with 20 mg of the dierent plasmids and performed by electroporation at 320 V and 960 mF using a Biorad Gene pulser II (Deckert et al., 1998) . Cells were grown in RPMI supplemented with 10% SVF and were stimulated with thrombin 48 h after electroporation. For stable transfection, selection of transfected cells was made by dilution in the presence of 2 mg/ml of geneticine.
Csk kinase assay
For immunoprecipitation, lysates were incubated with protein-A sepharose beads precoated with anti-Csk antibody. The immune complexes were washed three times with lyzis buer and then twice with phosphate buer saline (PBS). The samples were subjected to an in vitro kinase assay as described previously. Brie¯y, the sample were resuspended in 50 ml kinase buer (30 mM HEPES, pH 6.8, 1 mM ATP, 10 mCi g-32 -PATP, 3 mM MgC1 2 ) containing 10 mg of acasein as substrate. After 30 min at 378C, reaction was stopped by addition of SDS sample buer. Samples were then separated on 10% polyacrylamide gels. Gels were dried and exposed for autoradiography.
Tyrosine phosphorylation and immunoblotting analysis
Jurkat T cells (3610 6 cells/condition) were stimulated for the indicated times at 378C with or without thrombin (100 nM). Stimulation was terminated by rapidly chilling the cells in liquid nitrogen. Cells were then solubilized in lysis buer A containing 50 mM HEPES, pH 7.4, 150 mM NaC1, 20 mM EDTA, 10 mM sodium orthovanadate, 100 mM NaF, 1% Nonidet P-40 and a cocktail of protease inhibitors (5 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride. 1 mM pepstatine) for 30 min on ice and then centrifuged at 48C for 15 min at 13 000 r.p.m. Supernatants were analysed on SDSpolyacrylamide gels and transferred to immobilon membranes (Millipore). Membranes were then blocked for 2 h at room temperature with 3% (w/v) BSA and probed overnight with phospho-speci®c p38 MAPK or phospho-speci®c ERK1/ 2 antibodies. Blots were ®nally incubated with horseradish peroxydase and immunoreactivity was revealed by enhanced chemoluminescence.
Subcellular fractionment
Stimulated or unstimulated Jurkat T cells were resuspended in hypotonic buer (100 mM Tris-HC1 pH 7.4, 5 mM EGTA supplemented with a cocktail of protease inhibitors as described before) and sonicated 20 s in ice. After adjusting the homogenates to 150 mM NaC1, intact cells and nuclei were removed by centrifugation at 1600 g for 5 min. The supernatants were then separated into soluble (S100) and particulate (P100) fractions by centrifugation at 100 000 g for 30 min at 48C. The pellets were resuspended in lysis buer A and sonicated. Aliquots of proteins in each fractions were resuspended in SDS sample buer, boiled for 5 min, analysed on 10% SDS-polyacrylamide gels and then transferred to immobilon membrane. Membranes were treated as described before and probed with anti-isoform speci®c PKC antibodies.
